[Connecticut Session] Lessons in Herding Cats: Strategic Opportunities for Life Science Companies

Add this event to your calendar:
14/11/2017 11:30 14/11/2017 14:00 America/New_York [Connecticut Session] Lessons in Herding Cats: Strategic Opportunities for Life Science Companies UConn Farmington - Cell & Genome Sciences Building , , , Johnson & Johnson Innovation, JLABS false DD/MM/YYYY
November
14
Event

[Connecticut Session] Lessons in Herding Cats: Strategic Opportunities for Life Science Companies

UConn Farmington - Cell & Genome Sciences Building , , ,

November 14, 2017 from 11:30 AM to 14:00 PM (EST)

$10 - $35


What are the ins and outs of making a partnership, from the perspective of a strategic investor?

The business development professional’s purpose is to optimize optionality and long term value at each stage of a company’s life. How do you determine the direction that will add the most value to your company? How do you avoid the constant pursuit of “shiny objects”? How do you know when it’s the right time for a strategic partnership?

In this workshop, you’ll hear from a dealmaking team at Johnson & Johnson Innovation and learn fundamental business development skills to help you successfully evaluate and manage strategic alliances and other potential growth opportunities.

Topics will include:

  • Strategic alliance process management
  • Concepts in valuation
  • Technical diligence
  • Communication and negotiation skills

This workshop is geared towards business development professionals and management teams of life science startups.


Event Partner:
This event is produced in partnership with CURE: Connecticut's Bioscience Innovation Network, and the UConn Technology Incubation Program.

   


Speakers:
Jim Tobin | VP of Cardiovascular & Metabolic Scientific Innovation, Johnson & Johnson Innovation read bio»
Erin Washington | Senior Manager, Transactions & Business Analytics, Johnson & Johnson Innovation read bio»


Agenda:
10:30 AM | Registration Opens and Networking
11:00 AM | Presentations
11:45 PM | Q&A
12:00 PM | Lunch and Networking
1:00 PM | Program Close


Fees:
$35 | General Public
FREE | Students, Faculty, & CURE Members
$45 | Onsite


Location:
UConn Farmington - Cell & Genome Sciences Building
Grossman Auditorium
400 Farmington Avenue
Farmington, CT 06032
Directions
Parking: Free, easy visitor parking is in front of the main entrance and, if full, use Area 3 parking in the lot just past and to the right of the building.


Speaker Biographies:
Jim Tobin, Ph.D. | Vice President of Cardiovascular & Metabolic Scientific Innovation, Johnson & Johnson Innovation
Jim is the Vice President of Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, Boston. He has over 19 years of drug development experience in the areas of hemostasis, inflammation, muscle degenerative diseases, and diabetes. Most recently, Jim was an entrepreneur-in-residence at Atlas Venture and focused on company formation in the life science sector. Prior to joining Atlas, Jim held the position of Vice President and Chief Scientific Officer at Pfizer leading a research unit focused on the development of biologics for the treatment of metabolic diseases and hemophilia. Prior to that he held the role of Vice President of Cardiovascular and Metabolic Diseases at Wyeth Pharmaceuticals and led the metabolic disease group with a focus on both small molecule and protein therapeutics in type 2 diabetes and muscle disease. Under Jim's direction these groups advanced over 15 biologics and small molecules into clinical development. Jim began his career at Genetics Institute (GI) where he was part of the structure based drug discovery group and was involved in the research and development of a number of biopharmaceutical products in inflammation, transplantation and thrombocytopenia, including the marketed product Neumega. Jim obtained his Ph.D. in Biochemistry from Brandeis University and completed his NRSA postdoctoral fellowship at Harvard University. He has authored 50 publications in peer-reviewed journals and is the inventor on 10 patents.
Connect with Jim:   Follow on Twitter   Connect on LinkedIn



Erin Washington | Senior Manager, Transactions & Business Analytics, Johnson & Johnson Innovation
Erin is responsible for developing and executing transactions with our diverse industry partners, including biotech companies, venture capital funds, non-profit organizations, governments, and academic institutions to access innovation across J&J’s areas of interest - our Pharmaceutical Therapeutic Areas, Consumer Need States, and Medical Device Businesses. She leads all aspects of the deal process, developing value-creating deal structures, managing term sheet and contract negotiations, and driving the business case development and approval process. Erin also provides business and commercial analytics capabilities to the Boston IC team. Prior to joining Johnson & Johnson, Erin was an Associate at Leerink Swann Consulting, where she advised on business development and corporate strategy for life sciences clients. Erin holds a BA in Organismic and Evolutionary Biology from Harvard University.
Connect with Erin:   Follow on Twitter   Connect on LinkedIn



Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), New York City, and with Shanghai opening in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact


Related content